Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Lawson

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Diabetes, Obesity & Metabolism|May 13, 2022
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trialMonika Kellerer, Margit Staum Kaltoft, Jack Lawson, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2020
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysisIldiko Lingvay, Matthew S Capehorn, Andrei-Mircea Catarig, et al.
Kidney International Reports|December 19, 2022
Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: <i>post hoc</i> Analysis of the SUSTAIN and PIONEER ProgramsDavid Z I Cherney, Samy Hadjadj, Jack Lawson, et al.
Journal of Veterinary Internal Medicine|March 2, 2026
Prevalence, breed predispositions, and culture and sensitivity results of bacterial hepatobiliary infections in dogs in the United KingdomFrederik Allan, Aarti Kathrani, Thomas Butler, et al.
Kidney International|February 4, 2023
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placeboKatherine R Tuttle, Heidrun Bosch-Traberg, David Z I Cherney, et al.
Diabetes, Obesity & Metabolism|July 21, 2021
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mgRichard E Pratley, Andrei-Mircea Catarig, Ildiko Lingvay, et al.
Veterinary Sciences|December 23, 2021
Renal Senescence, Telomere Shortening and Nitrosative Stress in Feline Chronic Kidney DiseaseJessica Quimby, Andrea Erickson, Shannon Mcleland, et al.
Diabetes Care|February 21, 2023
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 TrialsHiddo J L Heerspink, Ellen Apperloo, Melanie Davies, et al.
Cardiovascular Diabetology|May 27, 2023
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidenceMeir Schechter, Cheli Melzer Cohen, Alisa Fishkin, et al.
Marine Pollution Bulletin|January 25, 2022
Recommended metrics for quantifying underwater noise impacts on North Atlantic right whalesEmmaline Marotte, Andrew J Wright, Heather Breeze, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Diabetes, Obesity & Metabolism|May 13, 2022
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trialMonika Kellerer, Margit Staum Kaltoft, Jack Lawson, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2020
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysisIldiko Lingvay, Matthew S Capehorn, Andrei-Mircea Catarig, et al.
Kidney International Reports|December 19, 2022
Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: <i>post hoc</i> Analysis of the SUSTAIN and PIONEER ProgramsDavid Z I Cherney, Samy Hadjadj, Jack Lawson, et al.
Journal of Veterinary Internal Medicine|March 2, 2026
Prevalence, breed predispositions, and culture and sensitivity results of bacterial hepatobiliary infections in dogs in the United KingdomFrederik Allan, Aarti Kathrani, Thomas Butler, et al.
Kidney International|February 4, 2023
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placeboKatherine R Tuttle, Heidrun Bosch-Traberg, David Z I Cherney, et al.
Diabetes, Obesity & Metabolism|July 21, 2021
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mgRichard E Pratley, Andrei-Mircea Catarig, Ildiko Lingvay, et al.
Veterinary Sciences|December 23, 2021
Renal Senescence, Telomere Shortening and Nitrosative Stress in Feline Chronic Kidney DiseaseJessica Quimby, Andrea Erickson, Shannon Mcleland, et al.
Diabetes Care|February 21, 2023
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 TrialsHiddo J L Heerspink, Ellen Apperloo, Melanie Davies, et al.
Cardiovascular Diabetology|May 27, 2023
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidenceMeir Schechter, Cheli Melzer Cohen, Alisa Fishkin, et al.
Marine Pollution Bulletin|January 25, 2022
Recommended metrics for quantifying underwater noise impacts on North Atlantic right whalesEmmaline Marotte, Andrew J Wright, Heather Breeze, et al.
Pageof 3